DEXCOM INC — Director's Dealing 2023

Mar 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2023-03-06

Reporting Person: Dolan Matthew Vincent (SVP Corporate Strategy-Develop)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-06	Common Stock	S	226	$114.4	Disposed	26536	Direct

Footnotes

F1: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan which was amended on December 6, 2022. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: Included in this number are 26,536 unvested restricted stock units, 11,556 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,192 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,788 of which were granted on March 8, 2020 and shall vest through March 8, 2023.